Boost your Vaccine’s Immune Response with the world’s experts of scientific and sustainable solutions

What is QS-21?

It’s a fraction of triterpenoid saponins purified from bark extracts of the Quillaja saponaria Molina, an evergreen tree native to central Chile, being advantageously used in the formulation of adjuvants for prophylactic and therapeutic vaccines.

bg dots sm

A mixture of two isomeric molecules: QS-21-Xyl and QS-21 Api.

bg.lab

An outstanding immunostimulant agent, capable of inducing both humoral as well as cell mediated immunity.

img3

Its amphipathic nature makes it suitable for a range of vaccine formulations: liposomes, nanoparticles or emulsions.

bg dots

A mixture of two isomeric molecules: QS-21-Xyl and QS-21 Api.

bg.lab

An outstanding immunostimulant agent, capable of inducing both humoral as well as cell mediated immunity.

img3

Its amphipathic nature makes it suitable for a range of vaccine formulations: liposomes, nanoparticles or emulsions.

Advantages of a sustainable sourcing

  • It is a natural ingredient for vaccine formulation.
  • Lower antigen requirements, helping to potentiate weaker antigens.
  • Enhances duration and onset of immune response.
  • Augments antibody and helper/cytotoxic T-cell responses; when formulated with antigens, it triggers a balanced immune response.
  • Can be used independently or combined with other adjuvants: for example, AS01 and AS02 adjuvants from GSK; QS-21 + 3-O-desacyl-4’-monophosphoryl lipid A [MPL].
  • Because of its amphipathic properties, QS-21 is likely to stay in close proximity to the antigen, and it is suitable for a wide range of formulations with antigens and/or other adjuvants.

Pharmaceutical Applications

Quality and consistency guaranteed

How is produced QS-21?

A completely sustainable process that begins with the harvest
icon a

The Quillaja tree is preserved in this process

The Quillaja tree is preserved in this process; its biomass – wood, bark, leaves and roots – can be used to produce a range of products for various industries.
icon b

From a raw extract of Quillaja bark

Rich precursor (>70% on dry basis) is produced via the selective removal of non-saponin components (low and high molecular weight impurities).
icon c

Isolation of QS-21

Achieved through chromatographic purification.

How is produced QS-21?

A completely sustainable process that begins with the harvest

cover1

The Quillaja tree is preserved in this process

icon The Quillaja tree is preserved in this process; its biomass – wood, bark, leaves and roots – can be used to produce a range of products for various industries.
cover2

From a raw extract of Quillaja bark

icon Rich precursor (>70% on dry basis) is produced via the selective removal of non-saponin components (low and high molecular weight impurities).
cover3

Isolation of QS-21

icon Achieved through chromatographic purification.

Validation and efficacy

Summary of clinical trials involving QS-21 as an adjuvant*

  • Testing of vaccines containing QS-21 (alone or combined with other adjuvants): 114 clinical studies in humans (involving more than 140,000 subjects) have been undertaken.
  • Malaria has been the most studied case, in both the number of studies conducted as well as in number of subjects involved (131,000).
  • Current results demonstrate the efficacy of vaccines adjuvanted with QS-21 to boost immune response.
  • Found in approximately 17 human vaccine candidates, including areas of oncology, infectious disease and Alzheimer’s vaccines.
  • Currently in four Phase 3 clinical trials for Malaria, Melanoma, NSCLC and Shingles.
    Approved by FDA in combination with MPL, Oct. 2017**

Availability

Sustainable supply of raw material of Quillay for years to come

Our commitment is to conserve native forests through our innovative and sustainable forestry management model which reduces the impact on and revitalizes forests, contributing to their adaptation to climate change.

We seek to improve the management of the supply chain and work alongside all types of owners.

We are pioneers in the development of Quillay plantations of selected plants with increased contents of QS-21. (Patent pending.)

Aligned with the laws for the promotion and recovery of native forests, and we wish to contribute with techniques and development that allow the recovery and protection of natural resources.

Certificated with the FSC (Forest Stewardship Council®) seal in our biomass supply operation.

We develop and maintain lines of research focused on the requirements of Quillay as a crop, steadily advancing in the domestication process of the species and its intimate relationship with the ecosystem. Our efforts are aimed to reduce the strain on native forests.

bg banner
bg banner sm

Contact us

Do you want to receive more information or be contacted by us?

Write us an e-mail via the form, or just send us a direct email at info@desertking.com.

address
Phone: +1 619-429-5222
Fax: (619) 429-5001

Mail Address.
Desert King International
745 Main Street
Chula Vista, CA, USA, 91911

    Boost your Vaccine’s Immune Response with the world’s experts of scientific and sustainable solutions

    What is QS-21?

    It’s a fraction of triterpenoid saponins purified from bark extracts of the Quillaja saponaria Molina, an evergreen tree native to central Chile, being advantageously used in the formulation of adjuvants for prophylactic and therapeutic vaccines.

    bg dots sm

    A mixture of two isomeric molecules: QS-21-Xyl and QS-21 Api.

    bg.lab

    An outstanding immunostimulant agent, capable of inducing both humoral as well as cell mediated immunity.

    img3

    Its amphipathic nature makes it suitable for a range of vaccine formulations: liposomes, nanoparticles or emulsions.

    bg dots

    A mixture of two isomeric molecules: QS-21-Xyl and QS-21 Api.

    bg.lab

    An outstanding immunostimulant agent, capable of inducing both humoral as well as cell mediated immunity.

    img3

    Its amphipathic nature makes it suitable for a range of vaccine formulations: liposomes, nanoparticles or emulsions.

    Advantages of a sustainable sourcing

    • It is a natural ingredient for vaccine formulation.
    • Lower antigen requirements, helping to potentiate weaker antigens.
    • Enhances duration and onset of immune response.
    • Augments antibody and helper/cytotoxic T-cell responses; when formulated with antigens, it triggers a balanced immune response.
    • Can be used independently or combined with other adjuvants: for example, AS01 and AS02 adjuvants from GSK; QS-21 + 3-O-desacyl-4’-monophosphoryl lipid A [MPL].
    • Because of its amphipathic properties, QS-21 is likely to stay in close proximity to the antigen, and it is suitable for a wide range of formulations with antigens and/or other adjuvants.

    Pharmaceutical Applications

    Quality and consistency guaranteed

    How is produced QS-21?

    A completely sustainable process that begins with the harvest
    icon a

    The Quillaja tree is preserved in this process

    The Quillaja tree is preserved in this process; its biomass – wood, bark, leaves and roots – can be used to produce a range of products for various industries.
    icon b

    From a raw extract of Quillaja bark

    Rich precursor (>70% on dry basis) is produced via the selective removal of non-saponin components (low and high molecular weight impurities).
    icon c

    Isolation of QS-21

    Achieved through chromatographic purification.

    How is produced QS-21?

    A completely sustainable process that begins with the harvest

    cover1

    The Quillaja tree is preserved in this process

    icon The Quillaja tree is preserved in this process; its biomass – wood, bark, leaves and roots – can be used to produce a range of products for various industries.
    cover2

    From a raw extract of Quillaja bark

    icon Rich precursor (>70% on dry basis) is produced via the selective removal of non-saponin components (low and high molecular weight impurities).
    cover3

    Isolation of QS-21

    icon Achieved through chromatographic purification.

    Validation and efficacy

    Summary of clinical trials involving QS-21 as an adjuvant*

    • Testing of vaccines containing QS-21 (alone or combined with other adjuvants): 114 clinical studies in humans (involving more than 140,000 subjects) have been undertaken.
    • Malaria has been the most studied case, in both the number of studies conducted as well as in number of subjects involved (131,000).
    • Current results demonstrate the efficacy of vaccines adjuvanted with QS-21 to boost immune response.
    • Found in approximately 17 human vaccine candidates, including areas of oncology, infectious disease and Alzheimer’s vaccines.
    • Currently in four Phase 3 clinical trials for Malaria, Melanoma, NSCLC and Shingles.
      Approved by FDA in combination with MPL, Oct. 2017**

    Availability

    Sustainable supply of raw material of Quillay for years to come

    Our commitment is to conserve native forests through our innovative and sustainable forestry management model which reduces the impact on and revitalizes forests, contributing to their adaptation to climate change.

    We seek to improve the management of the supply chain and work alongside all types of owners.

    We are pioneers in the development of Quillay plantations of selected plants with increased contents of QS-21. (Patent pending.)

    Aligned with the laws for the promotion and recovery of native forests, and we wish to contribute with techniques and development that allow the recovery and protection of natural resources.

    Certificated with the FSC (Forest Stewardship Council®) seal in our biomass supply operation.

    We develop and maintain lines of research focused on the requirements of Quillay as a crop, steadily advancing in the domestication process of the species and its intimate relationship with the ecosystem. Our efforts are aimed to reduce the strain on native forests.

    bg banner
    bg banner sm

    Contact us

    Do you want to receive more information or be contacted by us?

    Write us an e-mail via the form, or just send us a direct email at info@desertking.com.

    address
    Phone: +1 619-429-5222
    Fax: (619) 429-5001

    Mail Address.
    Desert King International
    745 Main Street
    Chula Vista, CA, USA, 91911